
    
      Primary objective:

      To document and better define the prognostic characteristics of residual disability 12 months
      or more following an ischaemic stroke in patients that originally participated in the
      preceding clinical study RN-CS-0001.

      Other objective:

      To inform the design of efficient Phase 2/3 studies when screening potentially efficacious
      interventions for signals of activity which merit further development.
    
  